Olin and Huntsman shareholders approve all‑stock merger to form OlinHuntsman

Key highlights
  • Approximately 97% of votes cast at Olin's special meeting, representing 81% of outstanding shares, were in favor based on preliminary results.
  • Approximately 99% of votes cast at Huntsman's special meeting, representing 75% of outstanding shares, were in favor based on preliminary results.
  • The deal is an all‑stock merger of equals to create OlinHuntsman, described as a vertically integrated chemicals platform.
  • The transaction is expected to close in the first half of 2027, pending regulatory approvals, certification of final vote results and satisfaction or waiver of other customary closing conditions.

Shareholder approval

Olin and Huntsman reported that their respective shareholders approved the proposals necessary to complete the previously announced all‑stock merger of equals. Preliminary tallies showed roughly 97% of votes cast at Olin's special meeting (representing 81% of outstanding shares) and roughly 99% of votes cast at Huntsman's special meeting (representing 75% of outstanding shares) were in favor. Final results will be certified by independent inspectors of elections and reported in separate Form 8‑K filings.

Transaction and positioning

The companies said the merger will create OlinHuntsman, an integrated chemicals company. Management described the combined business as a value‑focused, vertically integrated platform positioned to serve customers across the value chain and deliver resilient financial performance.

Timing and closing conditions

Subject to receipt of required regulatory approvals and satisfaction or waiver of customary closing conditions, the transaction is expected to close in the first half of 2027. Both companies noted they remain committed to completing the remaining steps to close the deal.

Forward‑looking statements and risks

Olin and Huntsman cautioned that forward‑looking statements are subject to numerous risks and uncertainties, including failure to obtain regulatory approvals, potential delays or litigation, operational risks, and other factors described in their SEC filings.

Source: Huntsman

chemXplore Weekly

The week’s most important chemical-industry moves — analysed and summarised — delivered free every Wednesday.

Free. One email a week. Unsubscribe any time.